Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer

Podcast

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.

As part of the CancerNetwork® Between the Lines video series, Brian Helfand, MD, PhD, chief of the Division of Urology and the Ronald L. Chez Family and Richard Melman Family Endowed Chair at NorthShore University HealthSystem, and Steven Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates, part of the US Oncology Network, in Panama City, Florida, examined the results and clinical implications of the EMPIRE-1 trial (NCT01666808) in prostate cancer.1 The trial compares 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy.

In the video series, Helfand and Finkelstein discussed the following:

To watch more videos in the CancerNetwork® Between the Lines series, visit cancernetwork.com.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Reference

Jani AB, Schreibmann E, Goyal S, et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet. 2021;397(10288):1895-1904. doi:10.1016/S0140-6736(21)00581-X

Related Videos
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Related Content